Management of Hepatitis B Reactivation in Patients Receiving Cancer Chemotherapy

Overview

Journal Therap Adv Gastroenterol

Publisher Sage Publications

Specialty Gastroenterology

Date 2012 Sep 14

PMID 22973419

Citations 9

Authors

Yi-Wen Huang

Raymond T Chung

Affiliations

Soon will be listed here.

Abstract

Hepatitis B virus (HBV) reactivation is well documented in previously resolved or inactive HBV carriers who receive cancer chemotherapy. The consequences of HBV reactivation range from self-limited conditions to fulminant hepatic failure and death. HBV reactivation also leads to premature termination of chemotherapy or delay in treatment schedules. This review summarizes current knowledge of management of HBV reactivation in patients receiving cancer chemotherapy. HBV surface antigen (HBsAg) testing should be performed in patients who require cancer chemotherapy. Four meta-analyses support lamivudine prophylaxis for HBV reactivation during chemotherapy in HBsAg-positive patients. Randomized controlled trials to compare different HBV antiviral agents are needed to define optimal regimens for the prevention and treatment of HBV reactivation in patients receiving cancer chemotherapy.

Citing Articles

Implementation of a Hepatitis B Screening Program in Patients Receiving Systemic Anti-Cancer Therapy.

Leigh J, Mallick R, Brule S, Rambout L, Newton J, Bosse D Curr Oncol. 2025; 32(1).

PMID: 39851936 PMC: 11764458. DOI: 10.3390/curroncol32010020.

Universal Viral Screening of Patients with Newly Diagnosed Cancer in the United States: A Cost-efficiency Evaluation.

Vaidya R, Unger J, Loomba R, Hwang J, Chugh R, Tincopa M Cancer Res Commun. 2023; 3(9):1959-1965.

PMID: 37707388 PMC: 10541082. DOI: 10.1158/2767-9764.CRC-23-0255.

Efficacy of nucleos(t)ide analogues(NAs) in preventing virus reactivation in oncology patients with HBV infection after chemotherapy or surgery: A network meta-analysis.

Zhao Y, Song Y, Zhang H, Qu T, Axinbai M, Yang Y Front Oncol. 2023; 12:1050714.

PMID: 36727050 PMC: 9885183. DOI: 10.3389/fonc.2022.1050714.

Case Report: Vaccination by Autologous CD16 Dendritic Cells and Anti-PD-L 1 Antibody Synergized With Radiotherapy To Boost T Cells-Mediated Antitumor Efficacy In A Psoriatic Patient With Cutaneous Squamous Cell Carcinoma.

Huang J, Kuo C, Wang L, Ma K, Huang W, Liu F Front Immunol. 2022; 12:752563.

PMID: 35003064 PMC: 8733210. DOI: 10.3389/fimmu.2021.752563.

Association of Bcr-Abl Tyrosine Kinase Inhibitors With Hepatitis B Virus Reactivation Requiring Antiviral Treatment in Taiwan.

Wang L, Chu S, Lo Y, Yang Y, Chan K JAMA Netw Open. 2021; 4(4):e214132.

PMID: 33822067 PMC: 8025118. DOI: 10.1001/jamanetworkopen.2021.4132.

References

Perez-Roldan F, Gonzalez-Carro P, Villafanez-Garcia M . Adefovir dipivoxil for chemotherapy-induced activation of hepatitis B virus infection. N Engl J Med. 2005; 352(3):310-1. DOI: 10.1056/NEJM200501203520324. View

Cheng J, Liu M, Tsai S, Fang W, Jian J, Sung J . Unexpectedly frequent hepatitis B reactivation by chemoradiation in postgastrectomy patients. Cancer. 2004; 101(9):2126-33. DOI: 10.1002/cncr.20591. View

King L, Chung R . When treating cancer, please don't forget hepatitis B. Oncologist. 2010; 15(8):826-9. PMC: 3228019. DOI: 10.1634/theoncologist.2009-0282. View

Weinbaum C, Mast E, Ward J . Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. Hepatology. 2009; 49(5 Suppl):S35-44. DOI: 10.1002/hep.22882. View

Mendez-Navarro J, Corey K, Zheng H, Barlow L, Jang J, Lin W . Hepatitis B screening, prophylaxis and re-activation in the era of rituximab-based chemotherapy. Liver Int. 2010; 31(3):330-9. PMC: 3736143. DOI: 10.1111/j.1478-3231.2010.02332.x. View

Ohtsu T, Sai T, Oka M, Sugai Y, Tobinai K . Activation of hepatitis B virus infection by chemotherapy containing glucocorticoid in hepatitis B virus carriers with hematologic malignancies. Jpn J Clin Oncol. 1991; 21(5):360-5. View

Galbraith R, Eddleston A, Williams R, Zuckerman A . Fulminant hepatic failure in leukaemia and choriocarcinoma related to withdrawal of cytotoxic drug therapy. Lancet. 1975; 2(7934):528-30. DOI: 10.1016/s0140-6736(75)90897-1. View

Yeo W, Chan T, Leung N, Lam W, Mo F, Chu M . Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol. 2008; 27(4):605-11. DOI: 10.1200/JCO.2008.18.0182. View

Lim L, Wai C, Lee Y, Kong H, Lim R, Koay E . Prophylactic lamivudine prevents hepatitis B reactivation in chemotherapy patients. Aliment Pharmacol Ther. 2002; 16(11):1939-44. DOI: 10.1046/j.1365-2036.2002.01364.x. View

10.

Saab S, Dong M, Joseph T, Tong M . Hepatitis B prophylaxis in patients undergoing chemotherapy for lymphoma: a decision analysis model. Hepatology. 2007; 46(4):1049-56. DOI: 10.1002/hep.21783. View

11.

Yeo W, Chan P, Ho W, Zee B, Lam K, Lei K . Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy. J Clin Oncol. 2004; 22(5):927-34. DOI: 10.1200/JCO.2004.05.161. View

12.

Noterdaeme T, Longree L, Bataille C, Deroover A, Lamproye A, Delwaide J . Liver transplantation for acute hepatic failure due to chemotherapy-induced HBV reactivation in lymphoma patients. World J Gastroenterol. 2011; 17(25):3069-72. PMC: 3132261. DOI: 10.3748/wjg.v17.i25.3069. View

13.

Ji D, Cao J, Hong X, Li J, Wang J, Chen F . Low incidence of hepatitis B virus reactivation during chemotherapy among diffuse large B-cell lymphoma patients who are HBsAg-negative/ HBcAb-positive: a multicenter retrospective study. Eur J Haematol. 2010; 85(3):243-50. DOI: 10.1111/j.1600-0609.2010.01474.x. View

14.

Yeo W, Chan P, Chan H, Mo F, Johnson P . Hepatitis B virus reactivation during cytotoxic chemotherapy-enhanced viral replication precedes overt hepatitis. J Med Virol. 2001; 65(3):473-7. View

15.

Cortelezzi A, Vigano M, Zilioli V, Fantini N, Pasquini M, Deliliers G . Adefovir added to lamivudine for hepatitis B recurrent infection in refractory B-cell chronic lymphocytic leukemia on prolonged therapy with Campath-1H. J Clin Virol. 2005; 35(4):467-9. DOI: 10.1016/j.jcv.2005.10.009. View

16.

Pelizzari A, Motta M, Cariani E, Turconi P, Borlenghi E, Rossi G . Frequency of hepatitis B virus mutant in asymptomatic hepatitis B virus carriers receiving prophylactic lamivudine during chemotherapy for hematologic malignancies. Hematol J. 2004; 5(4):325-8. DOI: 10.1038/sj.thj.6200396. View

17.

Lok A, McMahon B . Chronic hepatitis B: update 2009. Hepatology. 2009; 50(3):661-2. DOI: 10.1002/hep.23190. View

18.

Dai M, Wu P, Shyu R, Lu J, Chao T . Hepatitis B virus reactivation in breast cancer patients undergoing cytotoxic chemotherapy and the role of preemptive lamivudine administration. Liver Int. 2004; 24(6):540-6. DOI: 10.1111/j.1478-3231.2004.0964.x. View

19.

Jang J, Choi J, Bae S, Yoon S, Chang U, Kim C . A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemo-lipiodolization. Hepatology. 2006; 43(2):233-40. DOI: 10.1002/hep.21024. View

20.

Hui C, Cheung W, Au W, Lie A, Zhang H, Yueng Y . Hepatitis B reactivation after withdrawal of pre-emptive lamivudine in patients with haematological malignancy on completion of cytotoxic chemotherapy. Gut. 2005; 54(11):1597-603. PMC: 1774754. DOI: 10.1136/gut.2005.070763. View